Cryptococcal meningitis in a patient treated with infliximab.
Infliximab, a tumor necrosis factor-alpha inhibitor, is increasingly used for the therapy of different inflammatory conditions. We report the first case of cryptococcal meningitis in a patient treated with infliximab and other immunosuppressive agents, and review a further 5 reported cryptococcal infections. All of them involved fungal pneumonia. Outcome was favorable in all cases.
Muñoz
Patricia
P
Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, University of Madrid, 28007 Madrid, Spain. pmunoz@micro.hggm.es
Giannella
Maddalena
M
Valerio
Maricela
M
Soria
Teresa
T
Díaz
Fernando
F
Longo
Javier Lopez
JL
Bouza
Emilio
E
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D008297:Male; D016919:Meningitis, Cryptococcal / Q000139:chemically induced*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab